Elite Pharmaceuticals Files 8-K
Ticker: ELTP · Form: 8-K · Filed: 2026-04-02T08:05:23-04:00
Sentiment: neutral
Topics: 8-K, disclosure, filing
TL;DR
Elite Pharma filed an 8-K, likely routine disclosures. No major news yet.
AI Summary
Elite Pharmaceuticals Inc. filed an 8-K on April 2, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes an 8-K form, an exhibit (EX-99.1), and associated XBRL data files. No specific financial figures or material events were detailed in the provided text.
Why It Matters
This filing indicates Elite Pharmaceuticals is providing updates or disclosures required by the SEC, though the specific content is not detailed here.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant financial changes or negative events.
Key Players & Entities
- ELITE PHARMACEUTICALS INC /NV/ (company) — Filer
- 0001053369 (company) — CIK number for Elite Pharmaceuticals Inc.
- 2026-04-02 (date) — Filing Date
- 165 LUDLOW AVENUE NORTHVALE NJ 07647 (location) — Mailing and Business Address
FAQ
What specific information is disclosed under Regulation FD?
The provided text does not specify the content of the Regulation FD disclosure under Item 7.01.
Are there any new financial statements or exhibits filed with this 8-K?
Yes, the filing lists an 8-K form, EX-99.1, and associated XBRL data files under Item 9.01, but their content is not detailed.
What is the CIK number for Elite Pharmaceuticals Inc.?
The CIK number for Elite Pharmaceuticals Inc. is 0001053369.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 2, 2026.
What is the business address of Elite Pharmaceuticals Inc.?
The business address is 165 Ludlow Avenue, Northvale, NJ 07647.
From the Filing
EDGAR Filing Documents for 0001493152-26-014813 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001493152-26-014813 Filing Date 2026-04-02 Accepted 2026-04-02 08:05:23 Documents 13 Period of Report 2026-04-02 Items Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K form8-k.htm iXBRL 8-K 36631 2 EX-99.1 ex99-1.htm EX-99.1 8311 3 GRAPHIC ex99-1_001.jpg GRAPHIC 7434 Complete submission text file 0001493152-26-014813.txt 219171 Data Files Seq Description Document Type Size 4 XBRL SCHEMA FILE eltp-20260402.xsd EX-101.SCH 3023 5 XBRL LABEL FILE eltp-20260402_lab.xml EX-101.LAB 34239 6 XBRL PRESENTATION FILE eltp-20260402_pre.xml EX-101.PRE 22364 16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 2996 Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646 ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK : 0001053369 (see all company filings) EIN. : 223542636 | State of Incorp.: NJ | Fiscal Year End: 0331 Type: 8-K | Act: 34 | File No.: 001-15697 | Film No.: 26830699 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)